Piper Sandler raised the price target for the NeoGenomics Inc. (NASDAQ:NEO) stock to ‘an Overweight’. The rating was released on June 03, 2023, according to finviz. We previously noted in another research note published on March 29, 2023 by Stephens that downgraded the stock from an Overweight to an Equal-weight with a price target of $16 for NEO stock. The research report from BofA Securities has downgraded the stock from Buy to Neutral, with a price target set at $18. The stock was resumed by Stephens, who disclosed in a research note on January 18, 2023, to Overweight and set the price objective to $40.